Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

Go back to Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
(NASDAQ: LTRN) Delayed: 0.64 -0.03 (4.48%)
Previous Close $0.67    52 Week High $ 
Open $0.65    52 Week Low $ 
Day High $0.72    P/E N/A 
Day Low $0.64    EPS $ 
Volume 105,811